The AAV gene therapy, under co-development of Reyon Pharmaceutical and Neuracle Genetics, has received approval for phase 1/2a clinical trials in Canada

2023.05.02

Reyon Pharmaceutical signed a joint development agreement with Therabest for NK cell therapy

2023.04.11

Reyon Pharmaceutical signed an MOU with Connext for comprehensive business cooperation in the CDMO business

2022.12.14

Reyon Pharmaceutical signed an MOU with Protium Science for comprehensive business cooperation for CDMO business

2022.12.06

Reyon Pharmaceutical signed an MOU with Therabest for business cooperation to supply pDNA samples

2022.11.24

Reyon Pharmaceutical signed an MOU with T&R Biofab for the joint development and commercialization of next-generation hemostatic agents

2022.10.25

Reyon Pharmaceutical and Neuracle Science discuss launching follow-up clinical trials for new antibody drugs against neurodegenerative diseases

2022.10.24

A GMP clinical-grade gene-therapy mass production system by Reyon Pharmaceutical and Samsung Seoul Hospital is selected as a national project

2022.09.23

Reyon Pharmaceutical participates in Bioplus-Interpex Korea 2022 for partnership expansion

2022.08.03

Reyon Pharmaceutical signed an MOU with Aston Science for joint R&D and commercializing a plasmid-DNA cancer treatment vaccine

2022.06.09